Abstract:Abstract Background: The efficacy of pemetrexed associates with the expression of folate enzymes, however, few serological marker is available to predict its efficacy. Moreover, dynamic monitoring of circulating tumor cell (CTC) count can predict the outcome of tumor therapy, the progress of tumor and the overall survival of the patient. By quantitative determination of folate receptor-positive CTCs, this study investigated the correlation of its baseline values to the efficacy of pemetrexed and performed a dynamic monitoring study in non-small cell lung cancer (NSCLC) patients who underwent first-line platinum-based chemotherapy. Methods: This study enrolled 70 NSCLC patients who received first-line platinum-based chemotherapy. The CTCs were quantified by negative enrichment using immunomagnetic beads in combination with folate receptor-directed polymerase chain reaction(PCR) that allows secondary amplification of tiny amounts of CTCs in peripheral blood, thereby enhancing the sensitivity of detection. In this study, the CTC levels were examined by collecting 3mL of anti-ENTA whole blood samples before the treatment and after every chemotherapy, and followed up until progressive disease (PD) or completion of first-line chemotherapy. Based on the changes in CTC levels, we evaluated the correlation of the changes in CTC levels and the progress of the disease as well as the correlation of the CTC levels and the therapeutic outcomes. Results: The CTC level of seventy patients was 13.68 CU/3mL. Of twenty-two patients who received pemetrexed disodium/platinum combined therapy (AP/AC), the patients harboring high levels of folate receptor showed greater efficacy than those with low expression levels (8.7 Conclusions: The patients with high expression of folate receptor-positive CTCs appear to have superior response to pemetrexed than those with low expression. Additionally, the changes of CTC count can be used as a dynamic monitoring indicator in the treatment process to evaluate tumor burden and therapeutic outcomes. Citation Format: Xiaoxia Chen, Caicun Zhou, Xuefei Li. Correlation of baseline value of folate receptor-positive circulating tumor cells and efficacy of pemetrexed and dynamic monitoring study in non-small cell lung cancer patients receiving first-line platinum-based chemotherapy. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2252.

Thymidylate synthase expression and therapeutic effect analysis of pemetrexed in advanced lung adenocarcinoma]

Correlation Between Thymidylate Synthase Gene Polymorphisms and Efficacy of Pemetrexed in Advanced Non-Small Cell Lung Cancer

The Pemetrexed-Containing Treatments in the Non-small Cell Lung Cancer, is -/Low Thymidylate Synthase Expression Better Than +/high Thymidylate Synthase Expression? A Meta-analysis

Association between variable number of tandem repeat polymorphism of thymidylate synthase gene and efficacy of pemetrexed in the treatment of advanced non-small cell lung cancer

Association of genetic polymorphis of thymidylate synthase and methylene tetrahydro folate reductase with therapeutic effect of pemetrexed for treating advanced lung adenocarcinoma patients

Effect of Pemetrexed Plus Platinum for Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer

Thymidylate Synthase Predicts Poor Response to Pemetrexed Chemotherapy in Patients with Advanced Breast Cancer.

Pd-L1 Expression Indicates Favorable Prognosis for Advanced Lung Adenocarcinoma Patients Treated with Pemetrexed

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Clinical efficacy of pemetrexed in the treatment of non-small cell lung cancer with asymptomatic brain metastasis

Predictive Value of Thymidylate Synthase Expression in Advanced Colorectal Cancer Patients Receiving Fluoropyrimidine‐based Chemotherapy: Evidence from 24 Studies

Outcomes of Pemetrexed-based chemotherapies in HER2 -mutant lung cancers

TS Mrna Levels Can Predict Pemetrexed and Raltitrexed Sensitivity in Colorectal Cancer

Pemetrexed induces ROS generation and cellular senescence by attenuating TS‐mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC

Abstract 2252: Correlation of Baseline Value of Folate Receptor-Positive Circulating Tumor Cells and Efficacy of Pemetrexed and Dynamic Monitoring Study in Non-Small Cell Lung Cancer Patients Receiving First-Line Platinum-Based Chemotherapy

Early Detection of Thymidylate Synthase Resistance in Non-Small Cell Lung Cancer with FLT-PET Imaging

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

Predictive Value of Unmethylated RASSF1A on Disease Progression in Non-Small Cell Lung Cancer Patients Receiving Pemetrexed-Based Chemotherapy

Plasma TS Mrna Expression As a Potential Predictive Biomarker for Pemetrexed and Raltitrexed in Gastric Cancer.

Thymidylate Synthase Was Associated with Patient Prognosis and the Response to Adjuvant Therapy in Bladder Cancer

The Efficacy of Pemetrexed Combined Cis-platinum Chemotherapy for Patients with Advanced Non Small Cell Lung Cancer and the Effect on Serum Tumor Markers